TITLE

Dronedarone Approved

PUB. DATE
September 2009
SOURCE
Travel Medicine Advisor;Sep2009 Supplement, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article announces the U.S. Food and Drug Administration (FDA) approval of dronedarone for the maintenance of normal sinus rhythm in patients with history of atrial fibrillation and atrial flutter and to patients who have returned to sinus rhythm or who will undergo cardioversion. The approval was based on a large scale trial that showed the drug reduced cardiovascular hospitalization or death from any cause by 24% when compared to placebo. As opposed to amiodarone, the article claims that dronedarone is less lipohilic and has no iodine moiety.
ACCESSION #
43828765

 

Related Articles

  • Dronedarone. Coleman, Craig I.; White, C. Michael; Baker, William L. // Formulary;Feb2009, Vol. 44 Issue 2, p40 

    Atrial fibrillation (AF) is a major cause of morbidity and mortality and affects approximately 2.5 million people in the United States. Patients suffering from AF have an increased risk of cardiovascular events and death and have a decreased heath-related quality-of-life. Dronedarone, an...

  • Dronedarone Approved. Elliott, William T. // Primary Care Reports;Sep2009 Supplement, p2 

    The article reports that the Food and Drug Administration (FDA) in the U.S. has given approval for dronedarone, an anti-arrhythmic agent for maintenance of normal sinus rhythm in patients who used to suffer from atrial fibrillation or atrial flutter. Sanofi-Aventis will be marketing the drug...

  • Prediction of Uneventful Cardioversion and Maintenance of Sinus Rhythm From Direct-Current Electrical Cardioversion of Chronic Atrial Fibrillation and Flutter.  // JAMA: Journal of the American Medical Association;10/16/91, Vol. 266 Issue 15, p2071 

    Presents the abstract of the paper 'Prediction of Uneventful Cardioversion and Maintenance of Sinus Rhythm From Direct-Current Electrical Cardioversion of Chronic Atrial Fibrillation and Flutter,' by Isabelle C. Van Gelder and others from the Department of Cardiology, Thoraxcenter of the...

  • Dronedarone Approved.  // Clinical Cardiology Alert;Sep2009 Pharmacology Watch, p2 

    The article reports on the approval issued by the U.S. Food and Drug Administration (FDA) for the clinical use of anti-arrhythmic dronedarone to maintain normal sinus rhythm in patients with a history of atrial fibrillation or atrial flutter. The drug is indicated for patients who have returned...

  • Pharmacotherapy Options in Atrial Fibrillation: Focus on Vernakalant. Cheng, Judy W. M.; Rybak, Iwona // Clinical Medicine: Therapeutics;2009, Issue 1, p215 

    This article reviews the role of vernakalant in the management of atrial fi brillation (AF). Published data in English language were identifi ed from MEDLINE and Current Content database (both 1966 to January 30, 2009). Vernakalant is an antiarrhythmic agent with sodium and ultra-rapid potassium...

  • A perfect drug. Erlanson, Dan // Nature;3/31/2011, Vol. 471 Issue 7340, p672 

    The article offers information on the success of Paxpharma as the most successful antidepressant drug in history in the U.S. It mentions that the company succeed in its roll out due to the success of its placebo trial. Because of the shortage of materials in time for the launch of the product...

  • Dronedarone Approved. Elliott, William T. // Clinical Oncology Alert;Sep2009 Supplement, p2 

    The article reports that the U.S. Food & Drug Administration (FDA) has given approval to dronedarone, an anti-arrhythmic drug for the maintenance of sinus rhythm in patients who had atrial fibrillation or atrial flutter. In 2006, the FDA rejected the drug because of safety concerns in patients...

  • Cardiome Moving Toward Pivotal Studies of Oral Vernakalant in AF.  // Bioworld Week;7/21/2008, Vol. 16 Issue 29, p3 

    The article reports that Cardiome Pharma Corp. continues to move forward with an oral version of arrhythmia drug vernakalant, which demonstrated positive results in a Phase IIb study, though a new drug application for intravenous formulation of it remains under the U.S. Food and Drug...

  • Pradaxa primer: A guide to treatment with dabigatran etexilate. Garrett, Anna D. // Drug Topics;Jan2011, Vol. 155 Issue 1, p42 

    The article focuses on the approval of the U.S. Food and Drug Administration (FDA) for the use of dabigatran etexilate as treatment for patients with nonvalvular atrial fibrillation (AF) in October 2010. It states that the said medication is considered as the first oral anticoagulant being...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics